-
1
-
-
79952232216
-
Global cancer statistics
-
Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
2
-
-
0022969737
-
Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies
-
Weiss L., Grundmann E., Torhorst J., Hartveit F., Moberg I., Eder M., et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986, 150:195-203.
-
(1986)
J Pathol
, vol.150
, pp. 195-203
-
-
Weiss, L.1
Grundmann, E.2
Torhorst, J.3
Hartveit, F.4
Moberg, I.5
Eder, M.6
-
3
-
-
66149155832
-
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
-
Nordlinger B., Van Cutsem E., Gruenberger T., Glimelius B., Poston G., Rougier P., et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20:985-992.
-
(2009)
Ann Oncol
, vol.20
, pp. 985-992
-
-
Nordlinger, B.1
Van Cutsem, E.2
Gruenberger, T.3
Glimelius, B.4
Poston, G.5
Rougier, P.6
-
4
-
-
36749073541
-
Bringing unresectable liver disease to resection with curative intent
-
Wicherts D.A., de Haas R.J., Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol 2007, 33(Suppl. 2):S42-S51.
-
(2007)
Eur J Surg Oncol
, vol.33
, pp. S42-S51
-
-
Wicherts, D.A.1
de Haas, R.J.2
Adam, R.3
-
5
-
-
84887887741
-
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
-
Rossi L., Vakiarou F., Zoratto F., Bianchi L., Papa A., Basso E., et al. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res 2013, 5:377-385.
-
(2013)
Cancer Manag Res
, vol.5
, pp. 377-385
-
-
Rossi, L.1
Vakiarou, F.2
Zoratto, F.3
Bianchi, L.4
Papa, A.5
Basso, E.6
-
6
-
-
79959947067
-
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
-
Wong R., Cunningham D., Barbachano Y., Saffery C., Valle J., Hickish T., et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011, 22:2042-2048.
-
(2011)
Ann Oncol
, vol.22
, pp. 2042-2048
-
-
Wong, R.1
Cunningham, D.2
Barbachano, Y.3
Saffery, C.4
Valle, J.5
Hickish, T.6
-
7
-
-
84894598632
-
Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA
-
(abstr 3619)
-
Gruenberger T., Bridgewater J.A., Chau I., Alfonso P.G., Rivoire M., Lasserre S., et al. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA. J Clin Oncol 2013, 24. (Suppl, abstr 3619).
-
(2013)
J Clin Oncol
, vol.24
, Issue.SUPPL
-
-
Gruenberger, T.1
Bridgewater, J.A.2
Chau, I.3
Alfonso, P.G.4
Rivoire, M.5
Lasserre, S.6
-
8
-
-
84908153983
-
Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer
-
Varol U., Yildiz I., Salman T., Karabulut B., Uslu R. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer. Tumori 2014, 100(July-August (4)):370-376.
-
(2014)
Tumori
, vol.100
, Issue.4 JULY AUGUST
, pp. 370-376
-
-
Varol, U.1
Yildiz, I.2
Salman, T.3
Karabulut, B.4
Uslu, R.5
-
9
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
10
-
-
61549118453
-
Targeted therapies in lung cancer
-
Pirker R., Filipits M. Targeted therapies in lung cancer. Curr Pharm Des 2009, 15:188-206.
-
(2009)
Curr Pharm Des
, vol.15
, pp. 188-206
-
-
Pirker, R.1
Filipits, M.2
-
11
-
-
78049361913
-
Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer
-
Bertino E.M., Otterson G.A. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer 2010, 70:233-246.
-
(2010)
Lung Cancer
, vol.70
, pp. 233-246
-
-
Bertino, E.M.1
Otterson, G.A.2
-
12
-
-
38349189743
-
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
-
Grothey A., Hedrick E.E., Mass R.D., Sarkar S., Suzuki S., Ramanathan R.K., et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008, 26:183-189.
-
(2008)
J Clin Oncol
, vol.26
, pp. 183-189
-
-
Grothey, A.1
Hedrick, E.E.2
Mass, R.D.3
Sarkar, S.4
Suzuki, S.5
Ramanathan, R.K.6
-
13
-
-
79956107589
-
New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy
-
Lee H.Y., Lee K.S., Ahn M.-J., Hwang H.S., Lee J.W., Park K., et al. New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer 2011, 73:63-69.
-
(2011)
Lung Cancer
, vol.73
, pp. 63-69
-
-
Lee, H.Y.1
Lee, K.S.2
Ahn, M.-J.3
Hwang, H.S.4
Lee, J.W.5
Park, K.6
-
14
-
-
2942657615
-
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
-
Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2184-2191
-
-
Johnson, D.H.1
Fehrenbacher, L.2
Novotny, W.F.3
Herbst, R.S.4
Nemunaitis, J.J.5
Jablons, D.M.6
-
15
-
-
63049122188
-
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab
-
Sandler A.B., Schiller J.H., Gray R., Dimery I., Brahmer J., Samant M., et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009, 27:1405-1412.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1405-1412
-
-
Sandler, A.B.1
Schiller, J.H.2
Gray, R.3
Dimery, I.4
Brahmer, J.5
Samant, M.6
-
16
-
-
84866859311
-
Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria
-
Chung W.S., Park M.S., Shin S.J., Baek S.E., Kim Y.E., Choi J.Y., et al. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. AJR Am J Roentgenol 2012, 199:809-815.
-
(2012)
AJR Am J Roentgenol
, vol.199
, pp. 809-815
-
-
Chung, W.S.1
Park, M.S.2
Shin, S.J.3
Baek, S.E.4
Kim, Y.E.5
Choi, J.Y.6
-
17
-
-
72249083700
-
Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases
-
Chun Y.S., Vauthey J.-N., Boonsirikamchai P., Maru D.M., Kopetz S., Palavecino M., et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009, 302:2338-2344.
-
(2009)
JAMA
, vol.302
, pp. 2338-2344
-
-
Chun, Y.S.1
Vauthey, J.-N.2
Boonsirikamchai, P.3
Maru, D.M.4
Kopetz, S.5
Palavecino, M.6
-
18
-
-
84871802981
-
Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases
-
Shindoh J., Loyer E.M., Kopetz S., Boonsirikamchai P., Maru D.M., Chun Y.S., et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012, 30:4566-4572.
-
(2012)
J Clin Oncol
, vol.30
, pp. 4566-4572
-
-
Shindoh, J.1
Loyer, E.M.2
Kopetz, S.3
Boonsirikamchai, P.4
Maru, D.M.5
Chun, Y.S.6
-
19
-
-
34249085905
-
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria
-
Choi H., Charnsangavej C., Faria S.C., Macapinlac H.A., Burgess M.A., Patel S.R., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1753-1759
-
-
Choi, H.1
Charnsangavej, C.2
Faria, S.C.3
Macapinlac, H.A.4
Burgess, M.A.5
Patel, S.R.6
-
20
-
-
56749096759
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
-
Blazer D.G., Kishi Y., Maru D.M., Kopetz S., Chun Y.S., Overman M.J., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008, 26:5344-5351.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5344-5351
-
-
Blazer, D.G.1
Kishi, Y.2
Maru, D.M.3
Kopetz, S.4
Chun, Y.S.5
Overman, M.J.6
-
21
-
-
34250637909
-
The role and limitations of 18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings
-
Lubezky N., Metse U., Geva R., Nakache R., Shmeli E., Klausener J.M., et al. The role and limitations of 18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007, 11:472-478.
-
(2007)
J Gastrointest Surg
, vol.11
, pp. 472-478
-
-
Lubezky, N.1
Metse, U.2
Geva, R.3
Nakache, R.4
Shmeli, E.5
Klausener, J.M.6
-
22
-
-
35748963541
-
Current controversies in the surgical management of colorectal cancer metastases to the liver
-
Small R., Luberky N., Ben-Haim M. Current controversies in the surgical management of colorectal cancer metastases to the liver. Isr Med Assoc J 2007, 9:742-747.
-
(2007)
Isr Med Assoc J
, vol.9
, pp. 742-747
-
-
Small, R.1
Luberky, N.2
Ben-Haim, M.3
-
23
-
-
29144504049
-
The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases
-
Wiering B., Krabbe P.F., Jager G.J., Oyen W.J., Ruers T.J. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005, 104:2658-2670.
-
(2005)
Cancer
, vol.104
, pp. 2658-2670
-
-
Wiering, B.1
Krabbe, P.F.2
Jager, G.J.3
Oyen, W.J.4
Ruers, T.J.5
-
24
-
-
4344615981
-
Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET)
-
discussion 447-50
-
Fernandez F.G., Drebin J.A., Linehan D.C., Dehdashti F., Siegel B.A., Strasberg S.M. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004, 240:438-447. discussion 447-50.
-
(2004)
Ann Surg
, vol.240
, pp. 438-447
-
-
Fernandez, F.G.1
Drebin, J.A.2
Linehan, D.C.3
Dehdashti, F.4
Siegel, B.A.5
Strasberg, S.M.6
-
25
-
-
15944429402
-
Prospective evaluation of the impact of [18F]fluoro-2-deoxy-d-glucose positron emission tomography of resectable colorectal liver metastases
-
Truant S., Huglo D., Hebbar M., Ernst O., Steinling M., Pruvot F.R. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-d-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005, 92:362-369.
-
(2005)
Br J Surg
, vol.92
, pp. 362-369
-
-
Truant, S.1
Huglo, D.2
Hebbar, M.3
Ernst, O.4
Steinling, M.5
Pruvot, F.R.6
-
26
-
-
84877049819
-
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial
-
Nasti G., Piccirillo M.C., Izzo F., Ottaiano A., Albino V., Delrio P., et al. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer 2013, 108:1566-1570.
-
(2013)
Br J Cancer
, vol.108
, pp. 1566-1570
-
-
Nasti, G.1
Piccirillo, M.C.2
Izzo, F.3
Ottaiano, A.4
Albino, V.5
Delrio, P.6
-
27
-
-
11144354392
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
-
Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
-
(2004)
Nat Med
, vol.10
, pp. 145-147
-
-
Willett, C.G.1
Boucher, Y.2
di Tomaso, E.3
Duda, D.G.4
Munn, L.L.5
Tong, R.T.6
-
28
-
-
84055167359
-
Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST)
-
Jiang T., Kambadakone A., Kulkarni N.M., Zhu A.X., Sahani D.V. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012, 47:11-17.
-
(2012)
Invest Radiol
, vol.47
, pp. 11-17
-
-
Jiang, T.1
Kambadakone, A.2
Kulkarni, N.M.3
Zhu, A.X.4
Sahani, D.V.5
-
29
-
-
0347615101
-
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies
-
Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003, 21:3955-3964.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3955-3964
-
-
Morgan, B.1
Thomas, A.L.2
Drevs, J.3
Hennig, J.4
Buchert, M.5
Jivan, A.6
-
30
-
-
83755180887
-
Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis
-
Hirashima Y., Yamada Y., Tateishi U., Kato K., Miyake M., Horita Y., et al. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 2012, 130:2359-2365.
-
(2012)
Int J Cancer
, vol.130
, pp. 2359-2365
-
-
Hirashima, Y.1
Yamada, Y.2
Tateishi, U.3
Kato, K.4
Miyake, M.5
Horita, Y.6
-
31
-
-
53749092242
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma
-
Hahn O.M., Yang C., Medved M., Karczmar G., Kistner E., Karrison T., et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008, 26:4572-4578.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4572-4578
-
-
Hahn, O.M.1
Yang, C.2
Medved, M.3
Karczmar, G.4
Kistner, E.5
Karrison, T.6
-
32
-
-
84879793148
-
Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography
-
Osawa G., Yoshimatsu K., Yokomizo H., Okayama S., Sagawa M., Naritaka Y. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography. Cancer Chemother Pharmacol 2013, 72:209-215.
-
(2013)
Cancer Chemother Pharmacol
, vol.72
, pp. 209-215
-
-
Osawa, G.1
Yoshimatsu, K.2
Yokomizo, H.3
Okayama, S.4
Sagawa, M.5
Naritaka, Y.6
-
33
-
-
54849426228
-
Contrast-enhanced ultrasound for the characterization of focal liver lesions - diagnostic accuracy in clinical practice (DEGUM multicenter trial)
-
Strobel D., Seitz K., Blank W., Schuler A., Dietrich C., von Herbay A., Friedrich-Rust M., Kunze G., Becker D., Will U., Kratzer W., Albert F.W., Pachmann C., Dirks K., Strunk H., Greis C., Bernatik T. Contrast-enhanced ultrasound for the characterization of focal liver lesions - diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall Med 2008, 29:499-505.
-
(2008)
Ultraschall Med
, vol.29
, pp. 499-505
-
-
Strobel, D.1
Seitz, K.2
Blank, W.3
Schuler, A.4
Dietrich, C.5
von Herbay, A.6
Friedrich-Rust, M.7
Kunze, G.8
Becker, D.9
Will, U.10
Kratzer, W.11
Albert, F.W.12
Pachmann, C.13
Dirks, K.14
Strunk, H.15
Greis, C.16
Bernatik, T.17
-
34
-
-
84903310621
-
Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy
-
Arita J1, Ono Y., Takahashi M., Inoue Y., Takahashi Y., Saiura A. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. Ann Surg Oncol 2014, 21(Suppl. 3):S390-S397.
-
(2014)
Ann Surg Oncol
, vol.21
, pp. S390-S397
-
-
Arita, J.1.1
Ono, Y.2
Takahashi, M.3
Inoue, Y.4
Takahashi, Y.5
Saiura, A.6
-
35
-
-
84858124994
-
Dual-energy CT with single- and dual-source scanners: current applications in evaluating the genitourinary tract
-
Kaza R.K., Platt J.F., Cohan R.H., Caoili E.M., Al-Hawary M.M., Wasnik A. Dual-energy CT with single- and dual-source scanners: current applications in evaluating the genitourinary tract. Radiographics 2012, 32:353-369.
-
(2012)
Radiographics
, vol.32
, pp. 353-369
-
-
Kaza, R.K.1
Platt, J.F.2
Cohan, R.H.3
Caoili, E.M.4
Al-Hawary, M.M.5
Wasnik, A.6
-
36
-
-
84868327045
-
Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?
-
Kim Y.N., Lee H.Y., Lee K.S., Seo J.B., Chung M.J., Ahn M.J., et al. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?. Korean J Radiol 2012, 13:702-710.
-
(2012)
Korean J Radiol
, vol.13
, pp. 702-710
-
-
Kim, Y.N.1
Lee, H.Y.2
Lee, K.S.3
Seo, J.B.4
Chung, M.J.5
Ahn, M.J.6
-
37
-
-
84875998274
-
Markers of response for the antiangiogenic agent bevacizumab
-
Lambrechts D., Lenz H.-J., de Haas S., Carmeliet P., Scherer S.J. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013, 31:1219-1230.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1219-1230
-
-
Lambrechts, D.1
Lenz, H.-J.2
de Haas, S.3
Carmeliet, P.4
Scherer, S.J.5
-
38
-
-
24644486057
-
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy
-
Schott A.F., Roubidoux M.A., Helvie M.A., Hayes D.F., Kleer C.G., Newman L.A., et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005, 92:231-238.
-
(2005)
Breast Cancer Res Treat
, vol.92
, pp. 231-238
-
-
Schott, A.F.1
Roubidoux, M.A.2
Helvie, M.A.3
Hayes, D.F.4
Kleer, C.G.5
Newman, L.A.6
-
39
-
-
0033050164
-
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
-
Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
-
(1999)
J Clin Oncol
, vol.17
, pp. 460-469
-
-
Kuerer, H.M.1
Newman, L.A.2
Smith, T.L.3
Ames, F.C.4
Hunt, K.K.5
Dhingra, K.6
-
40
-
-
0028305674
-
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations
-
Mandard A.M., Dalibard F., Mandard J.C., Marnay J., Henry-Amar M., Petiot J.F., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994, 73:2680-2686.
-
(1994)
Cancer
, vol.73
, pp. 2680-2686
-
-
Mandard, A.M.1
Dalibard, F.2
Mandard, J.C.3
Marnay, J.4
Henry-Amar, M.5
Petiot, J.F.6
-
41
-
-
20044366529
-
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome
-
Ajani J.A., Mansfield P.F., Crane C.H., Wu T.T., Lunagomez S., Lynch P.M., et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005, 23:1237-1244.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1237-1244
-
-
Ajani, J.A.1
Mansfield, P.F.2
Crane, C.H.3
Wu, T.T.4
Lunagomez, S.5
Lynch, P.M.6
-
42
-
-
33644842988
-
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer
-
Rödel C., Martus P., Papadoupolos T., Füzesi L., Klimpfinger M., Fietkau R., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-8696.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8688-8696
-
-
Rödel, C.1
Martus, P.2
Papadoupolos, T.3
Füzesi, L.4
Klimpfinger, M.5
Fietkau, R.6
-
43
-
-
33847333193
-
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery
-
Rubbia-Brandt L., Giostra E., Brezault C., Roth A.D., Andres A., Audard V., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007, 18:299-304.
-
(2007)
Ann Oncol
, vol.18
, pp. 299-304
-
-
Rubbia-Brandt, L.1
Giostra, E.2
Brezault, C.3
Roth, A.D.4
Andres, A.5
Audard, V.6
-
44
-
-
78049457753
-
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases
-
Kishi Y., Zorzi D., Contreras C.M., Maru D.M., Kopetz S., Ribero D., et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010, 17:2870-2876.
-
(2010)
Ann Surg Oncol
, vol.17
, pp. 2870-2876
-
-
Kishi, Y.1
Zorzi, D.2
Contreras, C.M.3
Maru, D.M.4
Kopetz, S.5
Ribero, D.6
-
45
-
-
77954954904
-
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX
-
Klinger M., Tamandl D., Eipeldauer S., Hacker S., Herberger B., Kaczirek K., et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 2010, 17:2059-2065.
-
(2010)
Ann Surg Oncol
, vol.17
, pp. 2059-2065
-
-
Klinger, M.1
Tamandl, D.2
Eipeldauer, S.3
Hacker, S.4
Herberger, B.5
Kaczirek, K.6
-
46
-
-
84879690214
-
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
-
Loupakis F., Schirripa M., Caparello C., Funel N., Pollina L., Vasile E., et al. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013, 108:2549-2556.
-
(2013)
Br J Cancer
, vol.108
, pp. 2549-2556
-
-
Loupakis, F.1
Schirripa, M.2
Caparello, C.3
Funel, N.4
Pollina, L.5
Vasile, E.6
-
47
-
-
84867881665
-
Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival
-
Gruenberger T., Arnold D., Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol 2012, 21:309-315.
-
(2012)
Surg Oncol
, vol.21
, pp. 309-315
-
-
Gruenberger, T.1
Arnold, D.2
Rubbia-Brandt, L.3
-
48
-
-
84859110959
-
Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy
-
Chang H.H.L., Leeper W.R., Chan G., Quan D., Driman D.K. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 2012, 36:570-576.
-
(2012)
Am J Surg Pathol
, vol.36
, pp. 570-576
-
-
Chang, H.H.L.1
Leeper, W.R.2
Chan, G.3
Quan, D.4
Driman, D.K.5
-
49
-
-
84890442385
-
Comment on "Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab"
-
Bibeau F., Gil H., Castan F., Boissière-Michot F. Comment on "Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab". Br J Cancer 2013, 109:3127-3129.
-
(2013)
Br J Cancer
, vol.109
, pp. 3127-3129
-
-
Bibeau, F.1
Gil, H.2
Castan, F.3
Boissière-Michot, F.4
-
50
-
-
77956225027
-
Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases
-
Maru D.M., Kopetz S., Boonsirikamchai P., Agarwal A., Chun Y.S., Wang H., et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 2010, 34:1287-1294.
-
(2010)
Am J Surg Pathol
, vol.34
, pp. 1287-1294
-
-
Maru, D.M.1
Kopetz, S.2
Boonsirikamchai, P.3
Agarwal, A.4
Chun, Y.S.5
Wang, H.6
-
51
-
-
84930805289
-
Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use?
-
Dede K., Salamon F., Landherr L., Jakab F., Bursics A. Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use?. Pathol Oncol Res 2015, 21:173-179.
-
(2015)
Pathol Oncol Res
, vol.21
, pp. 173-179
-
-
Dede, K.1
Salamon, F.2
Landherr, L.3
Jakab, F.4
Bursics, A.5
-
52
-
-
37048998995
-
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
-
Ribero D., Wang H., Donadon M., Zorzi D., Thomas M.B., Eng C., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110:2761-2767.
-
(2007)
Cancer
, vol.110
, pp. 2761-2767
-
-
Ribero, D.1
Wang, H.2
Donadon, M.3
Zorzi, D.4
Thomas, M.B.5
Eng, C.6
|